-
公开(公告)号：US08080572B2
公开(公告)日：2011-12-20
申请号：US12949114
申请日：2010-11-18
IPC分类号： A61K31/4164 , A61K31/4196 , C07D233/54 , C07D249/08
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08338418B2
公开(公告)日：2012-12-25
申请号：US13298493
申请日：2011-11-17
IPC分类号： A61K31/5377 , A61K31/44 , A61K31/4155 , A61K31/41 , A61K31/415 , A61K31/4245 , C07D413/14 , C07D401/14 , C07D259/00 , C07D271/06 , C07D231/10
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20120214849A1
公开(公告)日：2012-08-23
申请号：US13298493
申请日：2011-11-17
IPC分类号： A61K31/4439 , A61K31/4178 , C07D401/06 , A61P9/12 , C07D233/90 , C07D401/14 , A61P29/00 , A61P3/10 , A61K31/4164 , C07D401/10
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20110230525A1
公开(公告)日：2011-09-22
申请号：US12949114
申请日：2010-11-18
IPC分类号： A61K31/4439 , A61K31/4164 , A61K31/41 , A61K31/4196 , A61P13/12
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，r，Z，X，R 3和R 5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US07863309B2
公开(公告)日：2011-01-04
申请号：US12507995
申请日：2009-07-23
IPC分类号： A61K31/4164 , A61K31/4196 , C07D233/54 , C07D249/08
CPC分类号： A61K31/4196 , A61K45/06 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D249/10 , C07D401/06 , C07D401/14 , C07D403/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
公开(公告)号：US20150065543A1
公开(公告)日：2015-03-05
申请号：US14521689
申请日：2014-10-23
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D513/14 , C07D233/64 , C07D213/64 , C07D233/70 , C07D231/14 , C07D249/08 , C07D233/68 , C07D403/10
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，Y，Z，Q，W，X和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20130245087A1
公开(公告)日：2013-09-19
申请号：US13685148
申请日：2012-11-26
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D233/64
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
公开(公告)号：US08344013B2
公开(公告)日：2013-01-01
申请号：US13413076
申请日：2012-03-06
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： A61K31/415 , C07D233/54
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
公开(公告)号：US07834041B2
公开(公告)日：2010-11-16
申请号：US12231858
申请日：2008-09-05
申请人： Seok-Ki Choi , Paul R. Fatheree , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Vivek Sasikumar
发明人： Seok-Ki Choi , Paul R. Fatheree , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Vivek Sasikumar
IPC分类号： A61K31/41 , C07D257/04
CPC分类号： C07C323/60 , C07C259/06 , C07D207/16 , C07D257/04 , C07D403/12
摘要： The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，R3，Z，X和R5-7如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20080269305A1
公开(公告)日：2008-10-30
申请号：US12148872
申请日：2008-04-23
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： A61K31/41 , C07D233/68 , A61K31/4174 , G01N33/53 , A61P9/04 , A61P9/12 , G01N33/566 , C07K14/705 , C07D403/08
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，Y，Z，Q，W，X和R 5 5-如本说明书中所定义，及其药学上可接受的盐 。 这些化合物具有AT＆lt; 1＆gt;受体拮抗剂活性和尿丙氨酸抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
-
-
-
-
-
-
-
-
搜索结果
114 条记录 (耗时 0.055 秒)
